Literature DB >> 11527705

Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.

D W Ludovici1, B L De Corte, M J Kukla, H Ye, C Y Ho, M A Lichtenstein, R W Kavash, K Andries, M P de Béthune, H Azijn, R Pauwels, P J Lewi, J Heeres, L M Koymans, M R de Jonge, K J Van Aken, F F Daeyaert, K Das, E Arnold, P A Janssen.   

Abstract

The synthesis and anti-HIV-1 activity of a series of diarylpyrimidines (DAPYs) are described. Several members of this novel class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) are extremely potent against both wild-type and a panel of clinically significant single- and double-mutant strains of HIV-1.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11527705     DOI： 10.1016/s0960-894x(01)00412-7

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  31 in total

1.  The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.

Authors:  Vigneshwaran Namasivayam; Murugesan Vanangamudi; Victor G Kramer; Sonali Kurup; Peng Zhan; Xinyong Liu; Jacob Kongsted; Siddappa N Byrareddy
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

2.  On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data.

Authors:  Paul J Lewi; Marc de Jonge; Frits Daeyaert; Luc Koymans; Maarten Vinkers; Jan Heeres; Paul A J Janssen; Eddy Arnold; Kalyan Das; Art D Clark; Stephen H Hughes; Paul L Boyer; Marie-Pierre de Béthune; Rudi Pauwels; Koen Andries; Mike Kukla; Donald Ludovici; Bart De Corte; Robert Kavash; Chih Ho; Paul J Lewis
Journal:  J Comput Aided Mol Des       Date:  2003 Feb-Apr       Impact factor: 3.686

3.  Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Authors:  Eugene L Asahchop; Mark A Wainberg; Richard D Sloan; Cécile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

4.  Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.

Authors:  Bingjie Qin; Xingkai Jiang; Hong Lu; Xingtao Tian; Florent Barbault; Li Huang; Keduo Qian; Chin-Ho Chen; Rong Huang; Shibo Jiang; Kuo-Hsiung Lee; Lan Xie
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

5.  From docking false-positive to active anti-HIV agent.

Authors:  Gabriela Barreiro; Joseph T Kim; Cristiano R W Guimarães; Christopher M Bailey; Robert A Domaoal; Ligong Wang; Karen S Anderson; William L Jorgensen
Journal:  J Med Chem       Date:  2007-10-06       Impact factor: 7.446

6.  Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz.

Authors:  Marilyn B Kroeger Smith; Lenea H Rader; Amanda M Franklin; Emily V Taylor; Katie D Smith; Richard H Smith; Julian Tirado-Rives; William L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2007-12-23       Impact factor: 2.823

7.  2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors.

Authors:  Joseph Rebehmed; Florent Barbault; Cátia Teixeira; François Maurel
Journal:  J Comput Aided Mol Des       Date:  2008-05-28       Impact factor: 3.686

8.  Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy.

Authors:  Christopher M Bailey; Todd J Sullivan; Pinar Iyidogan; Julian Tirado-Rives; Raymond Chung; Juliana Ruiz-Caro; Ebrahim Mohamed; William L Jorgensen; William Jorgensen; Roger Hunter; Karen S Anderson
Journal:  J Med Chem       Date:  2013-05-09       Impact factor: 7.446

9.  A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.

Authors:  Yven Van Herrewege; Guido Vanham; Jo Michiels; Katrien Fransen; Luc Kestens; Koen Andries; Paul Janssen; Paul Lewi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations.

Authors:  Jacob G Zeevaart; Ligong Wang; Vinay V Thakur; Cheryl S Leung; Julian Tirado-Rives; Christopher M Bailey; Robert A Domaoal; Karen S Anderson; William L Jorgensen
Journal:  J Am Chem Soc       Date:  2008-06-28       Impact factor: 15.419
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.